Intervention
Adjuvant Radiotherapy
ClinicalTrials.gov intervention label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 9 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
9 shownOmission of Adjuvant Radiotherapy in Low- and Intermediate-Risk Ductal Carcinoma In Situ After Breast-Conserving SurgeryNCT07762885 · 2026-07-01
RECRUITINGNegative/Low Hormone Receptor And/or HER2 POsitive Lobular Invasive Breast Carcinoma - A Real-World International Cohort StudyNCT07613151 · 2026-05-01
RECRUITINGEMERALD: Endocrine Therapy oMission With Radiation in ER+ Breast Cancer: Assessing Quality of Life and Disease Control: a Prospective Phase II TrialNCT06897488 · 2025-07-17
RECRUITINGNeoadjuvant SBRT Followed by Nab-Paclitaxel Combined With Toripalimab in HR+/HER2- Breast CancerNCT06914440 · 2025-06-05
RECRUITINGDe-escalation of RNI in Breast Cancer Patients With pN0 After Neoadjuvant TherapyNCT07724769 · 2026-06-01
NOT_YET_RECRUITINGEffects of Radiotherapy in Borderline and Malignant Phyllodes Tumors After R0 ResectionNCT06780059 · 2024-12-30
COMPLETEDPure Florid and Pleomorphic Lobular Carcinoma in Situ of the Breast: Towards an Increasingly Uniform ManagementNCT06133465 · 2023-10-15
COMPLETEDRadiotherapy - Adjuvant Versus Early SalvageNCT00860652 · 2009-03-03
ACTIVE_NOT_RECRUITINGRadiation Therapy After Surgery in Treating Women With Phyllodes Tumor of the BreastNCT00003404 · 1998-01-01
COMPLETEDCommon conditions
Leading sponsors
Trial status mix
RECRUITING4
COMPLETED3
ACTIVE_NOT_RECRUITING1
NOT_YET_RECRUITING1
Phase mix
NA3
PHASE22
PHASE31
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.